FCM
NGNE icon

Farallon Capital Management’s Neurogene NGNE Stock Holding History

Farallon Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,405
Closed -$451K – 90
2014
Q2 		$451K Sell
2,405
-95
-4% -$18.3K 0.01% 97
2014
Q1 		$637K Buy
+2,500
New +$643K 0.01% 87

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Farallon Capital Management's NGNE Position: Q3 2014 in Review

Farallon Capital Management sold out of Neurogene (NGNE) in Q3 2014, closing a stake of 2,405 shares — an estimated $451K sold.

Farallon Capital Management first reported a position in NGNE in Q1 2014 and held it in 2 quarters. The position peaked at $637K in Q1 2014. 22 funds tracked by Wall St. Rank hold NGNE as of Q3 2014.

  • Farallon Capital Management reported no remaining Neurogene position as of Q3 2014 after selling out during the quarter.
  • Farallon Capital Management sold 2,405 Neurogene shares in Q3 2014, an estimated $451K.
  • Farallon Capital Management first reported a position in Neurogene in Q1 2014 and held it in 2 quarters.
  • Farallon Capital Management's Neurogene position peaked at $637K in Q1 2014.
  • 22 funds tracked by Wall St. Rank held Neurogene as of Q3 2014.

Based on Farallon Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.